New research suggests that people who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who end traditional diet and exercise programs.
Published data in a prominent medical journal shows that while obese people often shed a large proportion of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying these treatments should be aware of the potential of rapid weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass within about a year and a half.
Comparing Approaches
The research, which looked at 37 of trials involving thousands of participants, contrasted the results of the injectable medications with conventional dieting.
Scientists emphasize that individuals who shed pounds through dieting typically experience a slower weight regain—around 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Doctors suggest the mechanism of the injections is key to understanding the accelerated regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication means hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Issue?
Health authorities suggest the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals contend that, considering the likelihood of weight regain, the therapy might need to be long-term.
This opinion is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent nature of obesity," comparing it to managing conditions like hypertension.
User Testimonies
People who have discontinued the medication describe a intense resurgence of cravings.
"I experienced something activating and I was suddenly extremely hungry," said an individual.
The struggle is compounded if users have not adopted lasting dietary or behavioural changes during therapy.
Growing Use
Recent estimates show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is more common among females compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone cure and lasting health benefits likely depends on combined lifestyle changes.
